CK0803 for Treatment of ALS

CK0803 is a neuroprotective regulatory T cell therapy for Amyotrophic Lateral Sclerosis (ALS). The FDA granted Orphan Drug Designation, and a randomized trial is planned for 2026. Early data suggest the approach can slow ALS progression and lower plasma neurofilament, a marker of active nerve damage and inflammation.